The role of prostaglandin E2 in renal cell cancer development: Future implications for prognosis and therapy

Future Oncology

Volumn 10, Issue 14, 2014, Pages 2177-2187

  Kaminska, Katarzyna ^a   Szczylik, Cezary ^a   Lian, Fei ^b   Czarnecka, Anna M ^a  

^a MILITARY INSTITUTE OF MEDICINE   (Poland)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

celecoxib; COX 2; cyclooxygenase 2; interferon; NSAID; PGE 2; prostaglandin; renal cell carcinoma; sunitinib

Indexed keywords

CYCLOOXYGENASE 2; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROSTAGLANDIN E RECEPTOR; PROSTAGLANDIN E2; PROTEIN KINASE B; PROTEIN TYROSINE KINASE INHIBITOR;

ARTICLE; CANCER PROGNOSIS; CANCER THERAPY; CARCINOGENESIS; DRUG EFFICACY; DRUG TARGETING; HUMAN; IMMUNOTHERAPY; KIDNEY CARCINOMA; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; UPREGULATION; ANIMAL; CARCINOMA, RENAL CELL; CELL TRANSFORMATION; KIDNEY NEOPLASMS; METABOLISM; PROGNOSIS;

ANIMALS; CARCINOMA, RENAL CELL; CELL TRANSFORMATION, NEOPLASTIC; CYCLOOXYGENASE 2; DINOPROSTONE; HUMANS; KIDNEY NEOPLASMS; PROGNOSIS; RECEPTORS, PROSTAGLANDIN E; SIGNAL TRANSDUCTION;

EID: 84916605955     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.14.152     Document Type: Article

References (70)

1. Schrader AJ, Hofmann R. Metastatic renal cell carcinoma: recent advances and current therapeutic options. Anti-cancer Drugs 19 (3), 235-245 (2008).
2. Cancer Facts and Figures 2012. American Cancer Society, GA, USA (2012).
3. Lungberg BC, Campbell CS, Choi HY et al Etiology and epidemiology. In: Kidney Cancer. Kirkali Z, Mulders P (Eds). International Consultation on Urological Diseases-European Association of Urology, Paris, France (2011).
4. Ritchie AW, Dekernion JB. The natural history and clinical features of renal carcinoma. Semin. Nephrol. 7(2), 131-139 (1987).
5. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. Cancer J. Clin. 59(4), 225-249 (2009).
6. Bruno JJ 2nd, Snyder ME, Motzer RJ, Russo P. Renal cell carcinoma local recurrences: impact of surgical treatment and concomitant metastasis on survival. BJU Int. 97(5), 933-938 (2006).
7. Therland KL, Stubbe J, Thiesson HC et al. Cycloxygenase-2 is expressed in vasculature of normal and ischemic adult human kidney and is colocalized with vascular prostaglandin E2 EP4 receptors. J. Am. Soc. Nephrol. 15 (5), 1189-1198 (2004).
8. Ohba K, Miyata Y, Watanabe S et al Clinical signifcance and predictive value of prostaglandin E2 receptors (EPR) 1-4 in patients with renal cell carcinoma. Anticancer Res. 31(2), 597-605 (2011).
9. Lee JW, Park JH, Suh JH et al Cyclooxygenase-2 expression and its prognostic signifcance in clear cell renal cell carcinoma. Korean J. Pathol. 46(3), 237-245 (2012).
10. Chang BD, Cao LS, Zhou HL. [Expression of COX-2 and VEGF and their correlation with angiogenesis in human clear cell renal cell carcinoma]. Zhonghua Zhong Liu Za Zhi 31(9), 687-690 (2009).
11. Sun H, Wang H, Qin WJ, Yang B, Wang SC, Jian BL. [Expression of IGF-IR and COX-2 in renal cell carcinoma and their relationship with cell proliferation]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 25(4), 348-350 (2009).
12. Li JF, Chu YW, Wang GM et al The prognostic value of peritumoral regulatory T cells and its correlation with intratumoral cyclooxygenase-2 expression in clear cell renal cell carcinoma. BJU Int. 103(3), 399-405 (2009).
13. Kim HS, Kim WS, Park SH et al Molecular biomarkers for advanced renal cell carcinoma: implications for prognosis and therapy. Urol. Oncol. 28(2), 157-163 (2010).
14. Dirim A, Haberal AN, Goren MR et al VEGF, COX-2, and PCNA expression in renal cell carcinoma subtypes and their prognostic value. Int. Virol. Nephrol. 40(4), 861-868 (2008).
15. Sozen S, Gurocak S, Erdem O et al Cyclooxygenase-2 expression: does it have a probable role in tumorigenesis mechanisms of renal cell carcinoma? Int. Urol. Nephrol. 40(2), 295-301 (2008).
16. Kankuri-Tammilehto MK, Soderstrom KO, Pelliniemi T T, Vahlberg T, Pyrhonen SO, Salminen EK. Prognostic evaluation of COX-2 expression in renal cell carcinoma. Anticancer Res. 30(7), 3023-3030 (2010).
17. Cho DS, Joo HJ, Oh DK et al Cyclooxygenase-2 and p53 expression as prognostic indicators in conventional renal cell carcinoma. Yonsei Med. J. 46(1), 133-140 (2005).
18. Tuna B, Yorukoglu K, Gurel D, Mungan U, Kirkali Z. Signifcance of COX-2 expression in human renal cell carcinoma. Urology 64(6), 1116-1120 (2004).
19. Hashimoto Y, Kondo Y, Kimura G et al Cyclooxygenase-2 expression and relationship to tumour progression in human renal cell carcinoma. HistoPathol. 44(4), 353-359 (2004).
20. Miyata Y, Koga S, Kanda S, Nishikido M, Hayashi T, Kanetake H. Expression of cyclooxygenase-2 in renal cell carcinoma: correlation with tumor cell proliferation, apoptosis, angiogenesis, expression of matrix metalloproteinase-2, and survival. Clin. Cancer Rese. 9 (5), 1741-1749 (2003).
21. Hao CM, Breyer MD. Physiological regulation of prostaglandins in the kidney. Annu. Rev. Physiol. 70, 357-377 (2008).
22. Nakanishi M, Rosenberg DW. Multifaceted roles of PGE2 in infammation and cancer. Semin. Immunopathol. 35(2), 123-137 (2013).
23. Taketo MM. Cyclooxygenase-2 inhibitors in tumorigenesis (part I). J. Natl Cancer Inst. 90 (20), 1529-1536 (1998).
24. Mungan MU, Gurel D, Canda AE, Tuna B, Yorukoglu K, Kirkali Z. Expression of COX-2 in normal and pyelonephritic kidney, renal intraepithelial neoplasia, and renal cell carcinoma. Eur. Urol. 50(1), 92-97; discussion 97 (2006).
25. Yoshimura R, Matsuyama M, Kawahito Y et al Study of cyclooxygenase-2 in renal cell carcinoma. Int. J. Mol. Med. 13(2), 229-233 (2004).
26. Khan Z, Khan N, Tiwari R P, Sah NK, Prasad GB, Bisen PS. Biology of Cox-2: an application in cancer therapeutics. Curr. Drug Targets 12(7), 1082-1093 (2011).
27. Saji S, Hirose M, Toi M. Novel sensitizing agents: potential contribution of COX-2 inhibitor for endocrine therapy of breast cancer. Breast Cancer 11(2), 129-133 (2004).
28. Hara S, Kondo Y, Matsuzawa I et al Expression of cycloxygenase-2 in human bladder and renal cell carcinoma. Adv. Exp. Med. Biol. 507, 123-126 (2002).
29. Wang X, Zhang L, O'neill A et al Cox-2 inhibition enhances the activity of sunitinib in human renal cell carcinoma xenografts. Br. J. cancer 108(2), 319-326 (2013).
30. Paul AG, Chandran B, Sharma-Walia N. Cyclooxygenase-2-prostaglandin E2-eicosanoid receptor infammatory axis: a key player in Kaposi's sarcoma-associated herpes virus associated malignancies. Transl. Res. 162(2), 77-92 (2013).
31. Duncan WC, Nio-Kobayashi J. Targeting angiogenesis in the pathological ovary. Reprod. Fertil. Dev. 25(2), 362-371 (2013).
32. Srivastava MK, Andersson A, Zhu L et al Myeloid suppressor cells and immune modulation in lung cancer. Immunotherapy 4(3), 291-304 (2012).
33. Konya V, Marsche G, Schuligoi R, Heinemann A. E-type prostanoid receptor 4 (EP4) in disease and therapy. Pharmacol. Ther. 138(3), 485-502 (2013).
34. Yef R, Ponce DP, Niechi I et al Protein kinase CK2 promotes cancer cell viability via up-regulation of cyclooxygenase-2 expression and enhanced prostaglandin E2 production. J. Cell. Biochem. 112 (11), 3167-3175 (2011).
35. Li Z, Zhang Y, Kim WJ, Daaka Y. PGE2 promotes renal carcinoma cell invasion through activated RalA. Oncogene 32(11), 1408-1415 (2013).
36. Rundhaug JE, Simper MS, Surh I, Fischer SM. The role of the EP receptors for prostaglandin E2 in skin and skin cancer. Cancer Metastasis Rev. 30(3-4), 465-480 (2011).
37. Fulton AM, Ma X, Kundu N. Targeting prostaglandin E EP receptors to inhibit metastasis. Cancer Res. 66(20), 9794-9797 (2006).
38. Ji R, Chou CL, Xu W, Chen XB, Woodward DF, Regan JW. EP1 prostanoid receptor coupling to G i/o up-regulates the expression of hypoxia-inducible factor-1 alpha through activation of a phosphoinositide-3 kinase signaling pathway. Mol. Pharmacol. 77(6), 1025-1036 (2010).
39. Yang L, Yuan J, Liu L et al alpha-linolenic acid inhibits human renal cell carcinoma cell proliferation through PPAR-gamma activation and COX-2 inhibition. Oncol. Lett. 6(1), 197-202 (2013).
40. Chen Q, Shinohara N, Abe T, Watanabe T, Nonomura K, Koyanagi T. Signifcance of COX-2 expression in human renal cell carcinoma cell lines. Int. J. Cancer J. Int. Cancer 108(6), 825-832 (2004).
41. Wu J, Zhang Y, Frilot N, Kim JI, Kim WJ, Daaka Y. Prostaglandin E2 regulates renal cell carcinoma invasion through the EP4 receptor-Rap GTPase signal transduction pathway. J. Biol. Chem. 286(39), 33954-33962 (2011).
42. Smyth GP, Stapleton PP, Barden CB et al Renal cell carcinoma induces prostaglandin E2 and T-helper type 2 cytokine production in peripheral blood mononuclear cells. Ann. Surg. Oncol. 10 (4), 455-462 (2003).
43. Woo SM, Min KJ, Chae IG, Chun KS, Kwon TK. Silymarin suppresses the PGE-induced cell migration through inhibition of EP2 activation; G protein-dependent PKA-CREB and G protein-independent Src-STAT3 signal pathways. Mol. Carcinog. doi:10.1002/mc.22092 (2013) (Epub ahead of print).
44. Network TCGaR. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature 499(7456), 43-49 (2013).
45. Schwandt A, Garcia JA, Elson P et al Clinical and immunomodulatory effects of celecoxib plus interferon-alpha in metastatic renal cell carcinoma patients with COX-2 tumor immunostaining. J. Clin. Immunol. 31(4), 690-698 (2011).
46. Rodriguez PC, Hernandez CP, Quiceno D et al Arginase I in myeloid suppressor cells is induced by COX-2 in lung carcinoma. J. Exp. Med. 202(7), 931-939 (2005).
47. Li J, Wang G, Chu Y, Rong R, Zhu T. The clinical application of COX-2 inhibitors may strengthen the sensitivity of renal cell carcinoma to immunotherapy. Med. hypotheses 71(4), 527-529 (2008).
48. + regulatory T cells: role of tumor COX-2-derived PGE2. Mol. Med. Rep. 3(6), 959-963 (2010).
49. Tate DJ, Jr., Vonderhaar DJ, Caldas YA et al Effect of arginase II on L-arginine depletion and cell growth in murine cell lines of renal cell carcinoma. J. Hematol. Oncol. 1, 14 (2008).
50. Gabrilovich D. Mechanisms and functional signifcance of tumour-induced dendritic-cell defects. Nat. Rev. Immunol. 4(12), 941-952 (2004).
51. Tate DJ, Jr., Patterson JR, Velasco-Gonzalez C et al Interferon-gamma-induced nitric oxide inhibits the proliferation of murine renal cell carcinoma cells. Int. J. Biol. Sci. 8(8), 1109-1120 (2012).
52. Sato N, Mizutani Y, Li YN et al Enhancement of the sensitivity of renal cell carcinoma cells to fas-mediated cytotoxicity and apoptosis by the selective cyclooxygenase-2 inhibitor JTE-522. Urol. Int. 84(3), 362-368 (2010).
53. Braun DP, Harris ZL, Harris JE et al Effect of interferon therapy on indomethacin-sensitive immunoregulation in the peripheral blood mononuclear cells of renal cell carcinoma patients. J. Biol. Response Mod. 2(3), 251-262 (1983).
54. Shinohara N, Kumagai A, Kanagawa K et al Multicenter Phase II trial of combination therapy with meloxicam, a cox-2 inhibitor, and natural interferon-alpha for metastatic renal cell carcinoma. Japanese J. Clin. Oncol. 39(11), 720-726 (2009).
55. Onishi T, Suzuki H, Igarashi T. [A case of favorable response after combination treatment with interferon-alpha and cyclooxygenase-2 inhibitor against metastatic renal cell carcinoma]. Hinyokika Kiyo. 58(1), 25-29 (2012).
56. Trelle S, Reichenbach S, Wandel S et al Cardiovascular safety of non-steroidal anti-infammatory drugs: network meta-analysis. BMJ 342, c7086 (2011).
57. Atala A. Re: Cox-2 inhibition enhances the activity of sunitinib in human renal cell carcinoma xenografts. J. Urol. 190(3), 1132 (2013).
58. Rainsford KD. Anti-infammatory drugs in the 21st century. Sub-Cell. Biochem. 42, 3-27 (2007).
59. Varas-Lorenzo C, Riera-Guardia N, Calingaert B et al Stroke risk and NSAIDs: a systematic review of observational studies. Pharmacoepidemiol. Drug Safety 20(12), 1225-1236 (2011).
60. Ochoa AC, Zea AH, Hernandez C, Rodriguez PC. Arginase, prostaglandins, and myeloid-derived suppressor cells in renal cell carcinoma. Clin. Cancer Res. 13(2 Pt 2), S721-S726 (2007).
61. + T-cell responses following overproduction of prostaglandin E2 by tumor cells in vivo. Cancer Res. 68(18), 7520-7529 (2008).
62. Salvado MD, Alfranca A, Haeggstrom JZ, Redondo JM. Prostanoids in tumor angiogenesis: therapeutic intervention beyond COX-2. Trends Mol. Med. 18(4), 233-243 (2012).
63. Tobert CM, Uzzo RG, Wood CG, Lane BR. Adjuvant and neoadjuvant therapy for renal cell carcinoma: a survey of the Society of Urologic Oncology. Urol. Oncol. 31(7), 1316-1320 (2013).
64. Choueiri M, Tannir N, Jonasch E. Adjuvant and neoadjuvant therapy in renal cell carcinoma. Curr. Clin. Pharmacol. 6(3), 144-150 (2011).
65. Jonasch E, Tannir NM. Adjuvant and neoadjuvant therapy in renal cell carcinoma. Cancer J. 14(5), 315-319 (2008).
66. Rini BI, Garcia JA, Cooney MM et al Toxicity of sunitinib plus bevacizumab in renal cell carcinoma. J. Clin. Oncol. 28 (17), e284-e285; author reply e286-e287 (2010).
67. Sosman J, Puzanov I. Combination targeted therapy in advanced renal cell carcinoma. Cancer 115(10 Suppl.), 2368-2375 (2009).
68. Sosman JA, Puzanov I, Atkins MB. Opportunities and obstacles to combination targeted therapy in renal cell cancer. Clin. Cancer Res. 13(2 Pt 2), S764-S769 (2007).
69. Korotkova M, Jakobsson PJ. Characterization of microsomal prostaglandin e synthase 1 inhibitors. Basic Clin. Pharmacol. Toxicol. 114 (1), 64-69 (2014).
70. Paul AG, Chandran B, Sharma-Walia N. Concurrent targeting of eicosanoid receptor 1/eicosanoid receptor 4 receptors and COX-2 induces synergistic apoptosis in Kaposi's sarcoma-associated herpesvirus and Epstein-Barr virus associated non-Hodgkin lymphoma cell lines. Transl. Res. 161(6), 447-468 (2013).